Drug induced pseudolymphoma

Magro, Cynthia M.; Daniels, Brianne H.; Crowson, A. Neil

doi:10.1053/j.semdp.2017.11.003

Cited by 34 publications

(58 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It may arise in response to a wide variety of factors (drug intake, arthropod assaults, infectious agents, and traumas) (Hussein, ). One of the precipitating factors for CPL are drugs like anticonvulsants, antidepressants, angiotensin‐converting enzyme inhibitors, and a variety of others (Magro, Daniels, & Crowson, ). Most often withdrawal of the drug with or without a short‐course of systemic steroids can lead to its resolution.…”

Section: Introductionmentioning

confidence: 99%

Lymphoma or pseudolymphoma: A report of six cases and review of the literature

Zhu

Zhang

Wang

et al. 2019

Dermatologic Therapy

View full text Add to dashboard Cite

To explore and compare the clinical presentations and pathologic features of cutaneous pseudolymphomas (CPL) with primary cutaneous lymphomas. Review literature in order to improve the treatment of CPL. Six cases of CPLs were collected. The clinical, pathologic, and immunohistochemical features were performed and analyzed in Peking Union Medical College Hospital in 2018. Of six patients, the distributions and clinical manifestations of skin lesions are varied. The pathologic features consisted of atypical prominent lymphocytes infiltration. Of them, two cases imitated mycosis fungoides, one case mimicked primary cutaneous aggressive pidermotropic CD8+ cytotoxic T‐cell lymphoma, one case was diagnosed as Jessner‐Kanof lymphocyte infiltration and two cases primary cutaneous CD4+ small/medium T‐cell lymphoproliferative disorder. With respect to etiology, one was result from insects bite and the others were on account of drugs. All cases were treated with systemic or local glucocorticoid. The skin lesions and systemic symptoms showed notable improvement after treatment. Follow‐up visits were 2 years, half a year, and months, respectively, without relapse. These unique types of CPL were similar to cutaneous lymphomas in clinical manifestation and pathology. They were all sensitive to the treatment of externally or orally using glucocorticoid. The prognosis is generally good but needs long‐term follow‐up.

show abstract

Section: Introductionmentioning

confidence: 99%

Lymphoma or pseudolymphoma: A report of six cases and review of the literature

Zhu

Zhang

Wang

et al. 2019

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…Pseudolymphomatous eruptions can be nodular and diffuse (resembling T‐and B‐cell lymphoma), epidermotropic, purpuric or granulomatous (resembling mycosis fungoides), and even angiocentric with CD30 expression (mimicking lymphomatoid papulosis). A common theme among these is immune dysregulation caused by the therapy, with resultant overactivity of the immune response . The presence of certain key features aids in the diagnosis of pseudolymphoma in this case including the absence of lymphocyte cell clonality, eosinophils and epithelioid‐cell granulomas.…”

Section: Discussionmentioning

confidence: 93%

“…Pseudolymphomas are divided into T‐cell subtype or B‐cell subtype depending on the immunohistochemical analysis . Drug‐induced pseudolymphoma has been associated with multiple classes of drugs including neuroleptics, antidepressants, antihistamines, angiotensin converting enzyme inhibitors, calcium channel blockers, and several biologic agents . Here we present a case of pseudolymphoma in the setting of ipilimumab/nivolumab administration.…”

Section: Introductionmentioning

confidence: 99%

Ipilimumab/nivolumab‐induced pseudolymphoma in a patient with malignant melanoma

et al. 2019

View full text Add to dashboard Cite

Combination therapy with ipilimumab and nivolumab is an adjuvant treatment approach for metastatic melanoma that boasts increased 3‐year survival when compared with a single immunotherapy agent. Combination therapy, however, is associated with increased toxicities, especially cutaneous side‐effects. Here we present a patient with metastatic melanoma and a sudden eruption of painful nodules on the face and arms 10 days after the administration of the fourth dose of combination ipilimumab/nivolumab. Biopsies demonstrated lymphoid hyperplasia, not clinically or pathologically consistent with an infectious, malignant or autoimmune etiology; a diagnosis of pseudolymphoma secondary to ipilimumab/nivolumab was made. After a steroid taper, the lesions resolved, and the patient was restarted on nivolumab monotherapy 2 weeks later without recurrence of symptoms or disease.

show abstract

“…Pseudolymphomas can be very difficult to differentiate histologically from cutaneous B‐cell lymphoma (CBCL) or CTCL, requiring careful clinical correlation to derive the correct diagnosis. Generally, once the inciting insult has been eliminated the process regresses spontaneously, although it has sometimes been reported to continue despite lack of continued exposure or even to occur without a known inciting cause . It is also possible to develop lymphoma years following the diagnosis of cutaneous pseudolymphoma .…”

Section: Discussionmentioning

confidence: 99%

“…There are many clinical and histopathological mimics of cutaneous T‐cell lymphoma (CTCL) in the literature, generally referred to as cutaneous pseudolymphomas, which can occur as a reaction to various insults including tattoos, vaccinations, infections, persistent contact dermatitis, and drugs, among others . We report a case of generalized fixed drug eruption mimicking CTCL.…”

Section: Introductionmentioning

confidence: 98%